## RARE: Ultragenyx Pharmaceutical Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -27.1% below STRENGTH zone (4.0-10.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-23.9% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($19.00)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bearish (Bullish: 0, Bearish: 3)

**1. Levi & Korsinsky Investigates Possible Securities Fraud by Ultragenyx Pharmaceutical Inc. (RARE)**
- Source: ACCESS Newswire | 20260102T102700 | Bearish | Relevance: 100%
- Levi & Korsinsky has initiated an investigation into Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) regarding potential securities law violations after the company's Phase III Orbit and Cosmic studies for setrusumab (UX143) failed to meet their primary endpoints. This announcement led to a significant drop in Ultragenyx's stock price, reaching a new 52-week low. The firm encourages affected investors to contact them to explore potential recovery under federal securities laws.

**2. Ultragenyx plans major cost-cutting push after flunking phase 3 brittle bone trials**
- Source: Fierce Biotech | 20260102T053700 | Bearish | Relevance: 100%
- Ultragenyx Pharmaceutical announced the failure of two late-phase trials for its brittle bone disease therapy, setrusumab, leading to immediate plans for significant expense reductions. Neither the Orbit nor the Cosmic study met the primary endpoint of reducing annualized fracture rates, despite demonstrating improvements in bone mineral density. The news caused Ultragenyx's stock to drop by 43%, and Mereo BioPharma, which holds European rights, saw its shares fall almost 90%.

**3. Bank of America Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $58.00**
- Source: MarketBeat | 20260102T170920 | Somewhat-Bearish | Relevance: 100%
- Bank of America lowered its price target for Ultragenyx Pharmaceutical (NASDAQ:RARE) from $72.00 to $58.00 but maintained a "buy" rating, indicating a potential 151.68% upside. Despite this and other recent price target cuts from various brokerages, the consensus rating for RARE remains a "Moderate Buy" with an average target of $74.18. The biopharmaceutical company reported a Q3 EPS miss and negative margins, though revenue increased by 14.6% year-over-year.

**4. Shareholders Alert: Investigation Into Ultragenyx Pharmaceutical Inc. (RARE) - Contact Levi & Korsinsky to Protect Your Rights**
- Source: ACCESS Newswire | 20251231T021012 | Bearish | Relevance: 100%
- Levi & Korsinsky has launched an investigation into Ultragenyx Pharmaceutical Inc. (RARE) following a significant stock price drop. This comes after the company announced that its Phase III Orbit and Cosmic studies for setrusumab failed their primary endpoints related to fracture rate reduction in Osteogenesis Imperfecta, leading to a 43.49% decline in stock value. Shareholders who experienced losses are encouraged to contact Levi & Korsinsky to explore potential recovery options.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.36M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.5% (-0.8%)
- JPMORGAN CHASE & CO: 8.3% (+146.0%)
- FMR, LLC: 7.6% (+179.6%)
- Blackrock Inc.: 6.7% (+2.7%)
- Sands Capital Manage: 3.9% (-4.4%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-23.9% 5d) with bearish MACD, trend may be turning.
2. Elevated short interest (9.2%): bears positioning against stock.
3. Long-term trend broken: trading 28.8% below SMA200.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Revenue growth strong at 21% YoY. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.3B |
| Beta | 0.16 |
| 52W Range | $18.41 - $46.50 |
| Short Interest | 9.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.24 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 deteriorating from -3.2% to -27.1% (-23.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 31.1pp (needs >4.0% for momentum thesis). AM_20 at -27.5% indicates price below own 20MA trend. Underperforming sector by 28.7pp, stock-specific weakness. Below SMA200 (0.71x), long-term trend not supportive. MACD histogram bearish (-1.48), momentum weakening. Elevated volume (2.3x 20MA), institutional activity likely. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -27.07% (CS: 50) | Weak |
| RSI_14 | 31.3 | Neutral |
| MACD Histogram | -1.48 | Bearish |
| vs SMA20 | 0.725x | Below |
| vs SMA50 | 0.715x | Below |
| vs SMA200 | 0.712x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $23.60
- **Stop Loss:** $19.00 (19.5% risk)
- **Target:** $28.20 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 313
- **Position Value:** $7,386.80
- **Portfolio %:** 7.39%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-12 (Est: $-1.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.21 | $-1.81 | -49.7% |
| 2025Q2 | $-1.32 | $-1.17 | +11.4% |
| 2025Q1 | $-1.64 | $-1.57 | +4.4% |
| 2024Q4 | $-1.27 | $-1.39 | -9.4% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_20*